Gynecologic Cancer
32% of older women who survived certain cancers report lower extremity lymphedema
Nearly one-third of older women who survived colorectal, endometrial or ovarian cancer reported lower extremity lymphedema, according to data published in JAMA Network Open.
Obesity, central adiposity may increase risk for future cancers
Obesity and elevated central adiposity were associated with increased risk for future cancers, including gastrointestinal and gynecologic cancer, researchers reported.
Hyperthermic intraperitoneal chemotherapy may benefit some women with ovarian cancer
Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or OS among women with advanced epithelial ovarian cancer, according to a single-blind, randomized study in JAMA Surgery.
Paclitaxel plus carboplatin ’preferred regimen of choice’ for gynecologic carcinosarcomas
Paclitaxel plus carboplatin demonstrated noninferiority to paclitaxel plus ifosfamide and should be a standard treatment for uterine carcinosarcoma, according to results of a phase 3 study published in Journal of Clinical Oncology.
Germline BRCA testing underused for women with ovarian cancer and commercial insurance
About one-third of women with commercial insurance underwent genetic testing for ovarian cancer between 2008 and 2018 despite unequivocal recommendations for universal testing, according to research in JAMA Network Open.
Cedars-Sinai Cancer names medical director of clinical trials office
B.J. Rimel, MD, has been named medical director of the Cedars-Sinai Cancer Clinical Trials Office.
Critical race theory in cancer research: Ask yourself ‘who is missing’
Critical race theory originated in a legal framework but has implications in the conduct of cancer research, according to Mya L. Roberson, PhD.
FDA approves FoundationOne CDx to identify patients with MSI-high tumors for pembrolizumab
The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab, according to a press release from the test’s manufacturer.
Cemiplimab extends survival vs. chemotherapy in recurrent cervical cancer
Cemiplimab extended OS compared with single-agent chemotherapy for women with recurrent cervical cancer, according to randomized phase 3 study results published in The New England Journal of Medicine.
Selinexor extends PFS in advanced endometrial cancer
Selinexor prolonged PFS compared with placebo among women with advanced or recurrent endometrial cancer, according to topline data released by the agent’s manufacturer.